Share Name Share Symbol Market Type Share ISIN Share Description
Shire Plc LSE:SHP London Ordinary Share JE00B2QKY057 ORD 5P
  Price Change % Change Share Price Shares Traded Last Trade
  -62.00p -1.39% 4,382.50p 1,744,002 16:35:09
Bid Price Offer Price High Price Low Price Open Price
4,374.50p 4,376.00p 4,434.00p 4,373.50p 4,420.00p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 11,224.63 3,149.21 348.72 12.1 39,862.4

Shire (SHP) Latest News (31)

More Shire News
Shire Takeover Rumours

Shire (SHP) Share Charts

1 Year Shire Chart

1 Year Shire Chart

1 Month Shire Chart

1 Month Shire Chart

Intraday Shire Chart

Intraday Shire Chart

Shire (SHP) Discussions and Chat

Shire Forums and Chat

Date Time Title Posts
20/7/201815:56ADDERALL XR sales boost Shire4,370
25/4/201808:04Easy-
24/4/201813:48Shire -
19/4/201822:57SHIRE Pharmaceuticals847
15/2/201722:25Time to Look at Shire (SHP)-

Add a New Thread

Shire (SHP) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Shire trades in real-time

Shire (SHP) Top Chat Posts

DateSubject
22/7/2018
09:20
Shire Daily Update: Shire Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SHP. The last closing price for Shire was 4,444.50p.
Shire Plc has a 4 week average price of 4,012.50p and a 12 week average price of 3,811p.
The 1 year high share price is 4,452.50p while the 1 year low share price is currently 2,940.50p.
There are currently 909,582,311 shares in issue and the average daily traded volume is 1,446,376 shares. The market capitalisation of Shire Plc is £39,862,444,779.58.
04/6/2018
11:48
badwood: It is not clear to me why the Takeda share price would necessarily go up significantly if Takeda shareholders voted down the merger for the following reasons: Firstly, they would incur a penalty fee for pulling out of the deal (someone suggested the penalty fee is around one $1bn) which would suppress the share price. Secondly, the chief executive Christophe Webber and most of the board would most probably have to resign or be sacked. That would create uncertainty which would have a serious negative impact on the share price. Thirdly, a number of commentators have put forward the view that Takeda needs to invigorate its pipeline of drugs, and without Shire their long term prospects look uncertain. Will the deal go ahead ? I assume that the majority of current Takeda shareholders are in it for the long haul. Therefore, those who vote to scupper the deal will be far more concerned with the burden of debt Takeda would be saddled with rather than the potential of a short term share price surge in the event of a no deal. A crucial consideration in all of this is the parts of Shire Christophe Webber intends to sell on and whether he has buyers lined up. Presumably he will provide guidance to Takeda shareholders before the vote.
30/5/2018
09:03
pete160: I also lightened up a few weeks ago, although still have 20% of pot in here, but I'm not sure I agree that the slide in the Takeda price is bad. The drop isn't really out of step with declines in the wider market and with the purchase partly funded with shares surely it provides Takeda holders some flexibility regardless of whether the share price halves or doubles? For SHP holders on the other hand, yes a reducing price is not necessarily good news - unless you are intending converting to Takeda to retain an exposure to SHP r&d going forward. But if the bid hadn't come along, what price do you think SHP would currently be trading at given that the market generally is down ? The self serving SHP directors hadn't exactly fallen over themselves to create value or comfort for their shareholders. If the bid hadn't come along I suspect SHP would currently be £ 26-28 / share, so even if the eventual Takeda bid is worth only say, £ 44, we are still much better off imo Finally, don't forget that between now and d'day sometime next Spring, presumably SHP is continuing to throw off bucket loads of cash. This was previously used to pay down debt rather than return to shareholders, but currently it is effectively reducing the risk to Takeda.
02/5/2018
12:06
badwood: scenario 1 The majority of hedge funds think the deal will fail so they buy Takeda and short Shire based on the assumption that if the deal fails Takeda share price will recover. This scenario would see Takeda share price rising and Shire share price falling. Currently, this doesn't appear to be happening. Also if Takeda share price were to rise significantly it would improve the chances of a deal happening. scenario 2 The majority of hedge funds think the deal will succeed and buy Shire. This scenario would see Shire price rise which is not happening. scenario 3 hedge funds short Takeda like there is no tomorrow to try to scupper the deal and at the same time short Shire. This is a high risk strategy and timing would be everything. So it seems that hedge funds are evenly split between those that think a deal will happen and those who think it will fail. I still think a deal will happen as: * Takeda are very determined * Takeda will have done their homework thoroughly * Japanese firms tend to be very committed to long term strategies * Takeda BoD will not want to lose face * Shire BoD recognise it's good value for shareholders in the short term
26/4/2018
07:53
pete160: Am i the only one that feels as if scfc and philanders continual 'the skies falling in' 'it's all doomed' take on things without any substance is becoming quite tiresome? Yes there are risks to the deal but do we need to be reminded of them 10 times each day. Presumably they have taken your own advice and do not hold any SHP shares ? I wouldn't be surprised if they have shorts and are willing the deal and the price to collapse ? Perhaps they could enlighten us mere mortals as to their involvement in this share? I personally have a £ 100k holding and I will be holding. If the deal goes through there will be at least a 15% uplift in the price from now (although it might take a year to get through regulators). If another bidder does emerge then it will need to be either a higher offer or more cash on the table or better shares and the gap from current to bid price will close. And if the deal doesn't go through, yes, there will be short term pain but either the current BOD will have to meaningfully address shareholder concerns and our returns, they'll be sacked or another bidder will take an interest. As for Takeda, the sky has not fallen in on their share price since this last offer for SHP (as some predicted!). Most of the pharma's are down on the year in any case, and Takeda realise that they need to get big or get taken out themselves. They will have sounded out their major shareholders already and their cost of debt is ultra cheap. They may well already have been approached by others to cherry pick the bits they might want to dispose of. Will another bidder come in ? Quite possibly .SHP is unique for it's current and future pipeline. At around the level of the current bid (which everyone agrees is pushing Takeda to the limit) the cost of acquiring this pipeline instantly is cheap relative to building one yourself. If someone with deeper pockets or more attractive shares come along then I think they will need to approach the board before May 8th extension, rather than wait for the board and Takeda to agree a lock out deal and penalty clauses (I suspect having gone this far, the Japanese will require a high level of certainty that they will get the prize)
25/4/2018
23:57
philanderer: Absolutely no point in any other bidder (which I doubt there is) showing their hand at the moment. Best to wait until may 8th expires, the Takeda offer flops and the SHP price drops back to the 3000p region. Market report: Rare disease specialist Shire lost 2.6 percent after it said it was willing to recommend a sweetened $64 billion offer from Takeda Pharmaceutical. The recent fall in its Japanese suitor's shares make the overall offer, comprised 21.75 pounds per share in cash and 27.26 pounds in new Takeda shares, less attractive. "Shareholders in Shire are likely to be a little concerned about getting a 50% stake in a company which has seen its share price nosedive in the last few months and which could well be worth considerably less by the time any deal is concluded", said CMC Markets analyst Michael Hewson. HTTPS://uk.finance.yahoo.com/news/shires-mega-deal-fails-lift-ftse-amid-global-093256217--finance.html?guccounter=1
25/4/2018
07:51
steeplejack: "If people bemoan that Takeda have got a bargain at this price, it is the fault of the SHP bod, no-one else."I'm not sure I agree with that.The industry,represented by Takeda,considers that Shire are worth,in current circumstances,around 49 pounds a share.Recently,the board of Shire were openly stating that they were bemused at the collapse in their share price.Most analysts,of course,as the share price fell,simply trimmed their share price targets which had been well over 50 pounds a year ago.You could argue that the Shire management failed to market themselves effectively to investors I suppose.Yet,it is impossible to avoid the thought that the City/Wall St,both failed to evaluate the shares correctly.That Takeda should pay a takeover premium of two thirds to a recent three year low in Shires share price,suggest that fund managers and commentators alike,were incompetent in correctly valuing Shire shares.
20/4/2018
09:39
paa65: Could Allergan be playing a smart game here?Avoid the bidding war. Let Takeda make a last bid (probably rejected again).See SHP share price fall again.And then come in with a better cash offer?
18/4/2018
17:22
karateboy: Two consecutive days share price dropped when USA market opened few days ago. Trend reversed now and Last two days share price moving higher after 15:00. Takeda CEO is reported visiting USA this week may be causing it or there is another bidder getting ready to join in. Hopefully share price will be £40 before any bidding starts. Big volume today almost twice the average daily trades and share price moves higher. That is good
07/4/2018
14:09
adamb1978: Does feel like an offer will be made at some point - whether its at a price which SHP would recommend or not though, I'm somewhat sceptical. Could potentially get into a situation where Takeda go to SHP's investors and try to strong arm management into a deal, and we see a couple increased offers. Even if it were rebuffed though, it would provide some pep to the share price, even after it was rejected. Also, can completely understand the comments that a lot of investors would take £45 per share. The share price has only be heading in one direction and the opportunity to take something like a 50% premium to where the price was prior to the speculation is something which financial investors would readily accept I feel.
01/4/2018
12:21
karateboy: Let's summarise what we know and what happens if take over is successful: 1. In 2014 a $54b takeover of SHP by Abbvie was called off due US tax rule. Is Abbvie still interested? 2. In 2016 SHP paid $32b for Baxalta..share price decline started then. However current share price does not give any value to this take over. 3. SHP and Tekeda combined will creat one of the biggest Pharma with revenue of $30b . I wonder if other big Pharma will let this to happen. So if Takeda makes the move, I believe other big Pharma may join the bid... 4. Takeda has no block buster drug in the pipeline, SHP has.so it may make sense for Takeda to take SHP over. 5. Takeda research centre is close by to SHP research centre in the USA...saving here... 6. Takeda CEO is ex big Pharma executive . He wants to run a big Pharma not just medium size Takeda. Interesting time ahead.
Shire share price data is direct from the London Stock Exchange
add chat code
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20180722 18:26:33